Clinical utility of emerging liquid biomarkers in advanced prostate ...

The therapeutic landscape of advanced prostate cancer (PCa) has rapidly expanded in recent years. Despite significant improvements in patient overall ...

The development of molecular biomarkers will be key for patient stratification, and for monitoring response and resistance to therapy. In this context, ...

Clinical utility of emerging biomarkers in prostate cancer liquid ...

Prostate specific antigen (PSA) monitoring and histopathological examination of tumor biopsies remain gold standards in PCa diagnostics. These clinical ...

Clinical utility of emerging liquid biomarkers in advanced prostate ...

Circulating tumor DNA (ctDNA) and tumor cells (CTCs) inform on metastatic tumor burden. •. AR changes in ctDNA and CTCs associate with poor response to AR- ...

Clinical utility of emerging biomarkers in prostate cancer liquid ...

Expert opinion: Liquid biomarkers have high potential to be used for prognosis, monitoring treatment response and guiding treatment selection. Although there is ...

Clinical utility of emerging biomarkers in prostate cancer liquid ...

Circulating tumor cells form new metastatic sites by gaining plasticity and motility through, for example, epithelial- mesenchymal transition ( ...

Clinical utility of emerging biomarkers in prostate cancer liquid ...

Expert opinion Liquid biomarkers have high potential to be used for prognosis, monitoring treatment response and guiding treatment selection.

Prostate Cancer Liquid Biopsy Biomarkers' Clinical Utility in ... - MDPI

Prostate cancer (PCa) is the most common cancer in men and the second most common cause of mortality in this population in the United States, with 191,930 new ...

Emerging Molecular Biomarkers in Advanced Prostate Cancer

Molecular biomarkers have the potential to help clinicians with risk stratification, inform patient selection for therapy, and assist patient and family ...

Liquid Biomarkers in Prostate Cancer Diagnosis

Emerging biomarkers, including non-coding RNAs, circulating tumor DNA, and prostate-specific antigen (PSA) glycosylation, offer valuable ...

Current advances of liquid biopsies in prostate cancer - Cell Press

The use of LB in PCa diagnosis and monitoring has great clinical importance. It avoids repeated unnecessary biopsies that cost time, money, and ...

Liquid Biopsy Based Circulating Biomarkers in Metastatic Prostate ...

Other clinically validated (serum and urine) biomarkers, when combined with PSA, showed improved diagnostic accuracy include Prostate cancer ...

Blood-based liquid biopsies for prostate cancer: clinical ... - Nature

ctDNA analysis of metastatic prostate cancer patients is able to identify prostate cancer genomic features. When the circulating tumour fraction ...

Clinical Applications of Liquid Biopsy in Prostate Cancer - MDPI

In advanced disease states, LB has proven prognostic ability in addition to standard-of-care tests like the prostate-specific antigen and has been used in ...

[PDF] Prostate Cancer Liquid Biopsy Biomarkers' Clinical Utility in ...

Current knowledge about non-invasive, cost-effective, high-accuracy liquid biopsy diagnostic biomarkers such as Progensa PCA3, MyProstateScore, ExoDx, ...

Prostate cancer and liquid biopsies: Clinical applications and ...

Consequently, there is a pressing need for improved biomarkers to aid clinicians in decision-making within these contexts. Cell-free DNA and ...

Liquid Biopsy Demonstrates Clinical Utility in Advanced Prostate ...

A new study assessed the genomic alterations identified by ctDNA analysis compared with tissue-based comprehensive genomic profiling in ...

Emerging biomarkers in the diagnosis of prostate cancer | PGPM

A large proportion of PCa are latent, never destined to progress or affect the patients' life. It is of utmost importance to identify which PCa ...

A clinical-grade liquid biomarker detects neuroendocrine ... - JCI

Neuroendocrine prostate cancer (NEPC) is an aggressive subtype, the presence of which changes the prognosis and management of metastatic ...

Clinical utility of emerging biomarkers in prostate cancer liquid ...

Publications that cite this publication · Pretreatment level of serum sialic acid predicts both qualitative and quantitative bone metastases of prostate cancer.